The median survival of patients with cystic fibrosis at present approaches 30 years.' Essentially, the ongoing medical and scientific struggle towards further improving this prognosis relies on In contrast to the lack of controlled data, many uncontrolled clinical observations have indicated that rhDNase does facilitate sputum clearance and many patients have reported that they find it much easier and more effective to raise secretions with the aid of rhDNase than without. Thus, presently established scientific evidence, together with everyday clinical experience, suggest that the observed changes in lung function are effected by enhanced clearance of secretions. It should be relatively easy to substantiate this hypothesis further in future clinical trials.
Long term effects
Here the question is whether the beneficial short term effects of rhDNase will translate into therapeutic long term effectiveness. The rationale behind expecting a beneficial effect on the course of the disease from improved clearance of secretions stems from our present understanding of the mechanisms of the disease. The proteolytic activity in the bronchial secretions of patients with cystic fibrosis is significantly increased, and this excessive proteolytic activity mainly stems from the host's own neutrophils. The effects of rhDNase on lung function not only decrease with time, but may be completely lost after the medication is terminated. One six month treatment study showed that, after stopping rhDNase, lung function dropped markedly below the initial baseline level. 25 When this pretreatment baseline value is plotted against that end point a slope of deterioration is obtained that does not differ substantially from the natural course of the disease. Concern arises as to whether treatment with rhDNase only effected a superficial removal of secretions while, deeper down on the mucosal surface, tissue damage continued as before. If so, therapy would only have effected some "lung function cosmetics" while having no impact on the long term progression of the disease. In a recently reported study, rhDNase failed to reduce the level of elastase and other inflammatory markers in the sputum and blood of patients with cystic fibrosis. 44 Thus, a beneficial long term effect of rhDNase is not yet firmly established from the available literature on its effects on lung function. Less attention has been paid to other outcome measures, but one six month multicentre study found a dose-dependent tendency towards fewer acute respiratory exacerbations with rhDNase treatment. 23 Supportive effects Effective clearance of secretions should make the bronchial mucosa of patients with cystic fibrosis more accessible for other inhaled medications such as antibiotics, amiloride, topical steroids, proteinase inhibitors, and gene therapy. As with chest physiotherapy, rhDNase could thus have a potential role as a facilitator of other aerosol medications. Valid studies to support this hypothesis, however, are lacking. One radioaerosol study demonstrated a more homogeneous deposition of tracer after rhDNase.36 Recent in vitro data indicate that rhDNase might be superior to other mucolytic agents in assisting the access of liposomal gene vectors to the cell surface,45 but here the question arises as to whether or not the enzyme will damage the therapeutic DNA-liposome complex.
Another potential supportive role of rhDNase which needs to be investigated is the possibility that it improves the antibacterial efficacy of antimicrobial agents. Antibiotic binding to sputum has been described by several investigators, and sputum DNA plays an important role in this phenomenon. 46 Other investigators, however, did not find a significant reduction in the serum level of antiPseudomonas precipitins after one year of treatment with rhDNase.54 It follows that the possibility of rhDNase enhancing the efficacy of inhaled or systemic antibacterial medication is as yet insufficiently explored. Clearly, this potential effect of rhDNase is an interesting and important issue that calls for further study.
Prescription
If it is correct that rhDNase has some therapeutic long term effectiveness, when, in the course of the disease, should such therapy commence? Patients with full blown suppurative lung disease will certainly provide more than sufficient substrate for the enzyme. An unresolved question, however, relates to the administration of rhDNase in mildly or moderately diseased patients and those with early stages of the disorder. There are arguments both for and against early prescription.
In general, clinical and radiological assessment, as well as conventional lung function testing and sputum bacteriology, tend to underestimate the amount of bronchial inflammation and infection in patients with seemingly mild or moderate lung disease. This is illustrated by bronchoalveolar lavage studies where evidence for a neutrophil-dominated increase in cells and abundant active elastase was found in clinically stable patients with only mildly compromised lung function.55 Others observed significantly increased DNA levels in the lavage fluid of infants with cystic fibrosis.56 Based on similar lavage findings, some authors have even postulated that chronic inflammation of the bronchial mucosa may commence before bacterial infection occurs.57 While this issue remains controversial, it is clear from the recent literature that mucosal inflammation may occur surprisingly early, and these findings would argue for a liberal and early prescription policy for rhDNase in clinical practice.
Such a liberal and early prescription policy, however, will, at least in some patients, result in unnecessarily high treatment costs. In addition, it could induce antibody formation in a few patients before their disease has progressed to a stage where they would really benefit from treatment. Furthermore, the question arises as to whether rhDNase could have any untoward effects in more mildly diseased patients who have so far maintained effective mucus transport. In an in vitro study using a frog palate model, rhDNase increased the transport velocity of those cystic fibrosis sputum samples with a decreased baseline mucociliary transport rate; however, it tended to decrease mucus transport velocity when added to other sputum samples with an increased baseline transport rate.33 This finding indicates the possibility that rhDNase may occasionally have a negative effect on mucus transport in patients with only mildly damaged mucosa. The pathophysiological explanation for this negative effect could be the aforementioned mechanical uncoupling of ciliary action and the mucus layer.
Thus, there are arguments for and against the early prescription of rhDNase. Obviously, the routine management of patients with cystic fibrosis does not provide sufficient information for a targeted and individualised indication. The question arises as to whether data from more invasive investigations such as fibreoptic bronchoscopy and bronchial lavage should be considered as a prerequisite for prescribing rhDNase to mildly and moderately diseased patients.
Interaction with other therapeutic strategies Other strategies for clearing excess bronchial secretions have a traditional position in the management of patients with cystic fibrosis, especially the various techniques of chest physiotherapy which have been developed to match the therapeutic needs of these patients specifically.58 Although applying a mechanical rather than a pharmacological concept of treatment, chest physiotherapy pursues the same goal as rhDNase. Surprisingly, however, no clinical studies to compare the relative benefit from these two different approaches have been undertaken. One recent in vitro study demonstrated an optimal effect on sputum spinnability when rhDNase and airflow oscillations were applied concomitantly.59 In general, cystic fibrosis caregivers tend to consider chest physiotherapy and rhDNase inhalation as complementary rather than competitive, but this concept is based exclusively on uncontrolled clinical observations. However, some other clinical observations might suggest a different perspective on this issue. In some European cystic fibrosis centres doctors were surprised that chest physiotherapists were able to predict whether or not a patient would respond with an improvement in lung function to newly prescribed rhDNase. Such foresight was (and is) usually based on the physiotherapist's indepth knowledge of the particular patient's chest physiotherapy skills and compliance. Thus, one is frequently able to predict a marked therapeutic response in those patients who produce significant amounts of sputum but comply badly with their daily chest physiotherapy routine. One can speculate that those recent studies that attempted to predict the lung function response to rhDNase of patients with cystic fibrosis4243 had to fail because they did not take into account the expertise and compliance with chest physiotherapy of the subjects.
The possibility therefore remains that regular inhalations of rhDNase might effectively replace the daily chest physiotherapy routine in some patients; in others, chest physiotherapy may be more effective than rhDNase, while a third subgroup might actually benefit from the presently prevailing strategy of combining these two therapeutic approaches. Finally, one can speculate that even if maximum clearance of secretions could be achieved by chest physiotherapy alone, rhDNase would be a valuable adjunct if it made mechanical clearance less time and energy consuming. At present, however, all these speculations lack any scientific background. It follows that the relative role of physical and pharmacological clearance of the airways in patients with cystic fibrosis needs to be more clearly defined by carefully conducted clinical studies.
The role of other mucolytic agents in the management of patients with cystic fibrosis has not been clearly established. There is the theoretical possibility of combining rhDNase with other mucolytic substances in an attempt to maximise their effects on viscoelasticity. Recent in vitro results indicate that combinations with nacystelyn, gelsolin, and hypertonic saline are, in fact, more effective on the viscoelastic properties of cystic fibrosis sputum than rhDNase alone. 60 62 Translating these results into a clinical experiment might, however, carry the risk of ineffective ciliary beating in the presence of large intrabronchial pools of liquefied secretions; in the presence of an additionally resulting mechanical handicap for coughing and chest physiotherapy, secretions might be shifted from one lung region to another rather than expectorated, and negative effects on the mechanics of breathing and on gas exchange might ensue.
Conclusions
In conclusion, the present widespread clinical use of rhDNase in the treatment of patients with cystic fibrosis is burdened by a range of unresolved problems and open questions. It seems the substance might have been introduced into the clinical routine too early, and this enthusiastic haste is being paid for with doubts on the ethics and cost effectiveness.
A liberal policy of prescribing rhDNase to all but the most mildly diseased patients will burden the health care system with considerable costs, will further complicate the daily therapeutic routine of patients by one more aerosol administration and, with a small but nevertheless finite risk of side effects, will be a load on the conscience of the caregiver. On the other hand, a very restrictive general prescription policy will burden the caregiver with the risk of withholding potentially valuable therapy and, in addition, such a position will be complicated by pressure towards more liberal prescription from patients, parents, and lay organisations.
A more targeted approach, based on a careful assessment of the disease in individual patients, might appear to be a more reasonable alternative; however, this remains only a theoretical option as there are no established criteria for effectively individualising treatment at present. As already mentioned, attempts at predicting the lung function response of the individual patient on the basis of sputum production and various other clinical parameters have failed.4243 Some groups promote the use of scoring systems, but these are based on arbitrarily chosen criteria and, so far, have not been validated. 63 Another frequently used method to individualise the prescription of rhDNase is a short therapeutic trial with closely monitored results. As outlined above, however, an easily assessed improvement in short term lung function cannot be extrapolated into clinically relevant long term benefits. To rely on the patient's own subjective assessment of therapeutic efficacy is also questionable as some patients report beneficial effects even in the presence of objectively documented deterioration.4' In summary, it remains unclear whether or not treatment with inhaled rhDNase has a positive impact on the long term course of the disease; if it does, no clearly defined criteria are available to identify those who will benefit.
It seems that in many cystic fibrosis centres the initial enthusiastic welcome for a promising new substance is turning into the more sober acknowledgment of a therapeutic problem. Clearly, the present insight into the potential and limitations of inhaled rhDNase is far from complete and more studies are urgently needed.
